Forest's Ceftaroline Data Robust Even Under New Antibiotic Efficacy Standards, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sensitivity analyses provide a way around proposed changes in FDA's data requirements for skin infections and community-acquired bacterial pneumonia.